Swiss startup Rivia closed a $15 million Series A to develop an agentic AI platform that unifies trial data in real time and to expand in US biotech hubs, notably Boston. The company plans product investments in Rivia Detect for continuous data‑quality monitoring and an agentic data‑quality product it says could save sponsors $2–5 million per trial. Earlybird led the round; Rivia emphasized prior performance of its Rivia Spark natural‑language analytics, which it presented as cutting Phase II data‑review timelines by 91% in a trial.